As of December 31 cash, cash equivalents and investments in marketable securities were $61.4M compared to $104.6M as of December 31. With the ...
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mersana Therapeutics (MRSN – Research Report), ...
Wedbush decreased their Q1 2025 earnings estimates for Mersana Therapeutics in a report issued on Monday, March 3rd. Wedbush ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback